Lakewood-Amedex doses first patient in Phase 2a Nu-3 trial for infected diabetic foot ulcers
LABT•Lakewood-Amedex Biotherapeutics dosed the first patient in its Phase 2a trial of Nu-3 for mildly infected diabetic foot ulcers, with topline data expected in Q1 2027.
1. Trial begins
The study aims to assess whether Nu-3 can control infection at the wound site. Readouts are intended to guide dose selection for a potential Phase 2b trial against placebo.
